Immunohistochemical Studies of the Kynurenine Pathway in Morphea

Rowland Noakes¹ and Nick Mellick²
¹Queensland Institute of Dermatology, Holland Park, Australia. ²Zenith Specialist Pathology, South Brisbane, Queensland, Australia.

ABSTRACT: Cutaneous sclerosis, resembling that seen in subcutaneous morphea, is a feature of eosinophilic fasciitis and eosinophilia-myalgia syndrome, two conditions in which the kynurenine pathway is known to be activated. To investigate the possibility of activation of the kynurenine pathway in morphea, skin biopsies were taken from involved and non-involved sites in a series of three patients with morphea. Immunohistochemical stains for quinolinic acid and indoleamine 2,3-dioxygenase (IDO) were performed.

KEYWORDS: Morphea, quinolinic acid, indoleamine 2,3-dioxygenase

Introduction
The ingestion of L-tryptophan is associated with eosinophilic fasciitis and the eosinophilia myalgia syndrome. Although initially attributed to the contaminant 1,1-ethylidenebis tryptophan detected in the product manufactured by Showa Denko, other authors have reported the same adverse reaction from L-tryptophan supplied by other manufacturers. Activation of the kynurenine pathway was reported in these patients as it was in patients suffering from the so called toxic oil syndrome. The latter was reported in Spain in 1981 as a result of adulterated rapeseed (canola) oil and shared many features with eosinophilia-myalgia syndrome and eosinophilic fasciitis. Further evidence supporting the role of quinolinic acid in eosinophilic fasciitis was published in 2006 when a human volunteer underwent a series of subcutaneous injections of quinolinic acid. A rise in the peripheral eosinophil count, cutaneous eosinophilic infiltration, and production of the fibrotic cytokine transforming growth factor (TGF) beta 1 by dermal dendrocytes and endothelial cells was reported. Little is known about the normal role of the kynurenine pathway in skin. N-methyl-D-aspartate (NMDA) receptors have been found to be present in non-neuronal tissue and have been demonstrated to have functional roles in keratinocytes. Fibroblasts express the kynurenine pathway with significant polymorphisms. On the basis of current knowledge, L-tryptophan is metabolized to quinolinic acid in leucocytes and keratinocytes, diffuses into dermal connective tissue, after which it enters the vascular and lymphatic plexuses before being transported to the liver for conversion to nicotinamide adenine dinucleotide (NAD). Indoleamine 2,3-dioxygenase (IDO), the rate limiting enzyme, is ubiquitous and found in many cell types. Activation occurs by both an increase in transcript number and enzyme activation. IDO activity increases with age. Overall the results favor increased activity of the kynurenine pathway in morphea with evidence of background activity in control specimens. The first two segments of the kynurenine pathways are expressed in the basal layer of the epidermis, eccrine units, and endothelium. The bulge area of the hair follicle has previously been reported as a site of relative immune privilege.
Materials and Methods
The study was undertaken at the Queensland Institute of Dermatology (P.O Box 277 Holland Park, QLD 4121 Australia www.qldid.com.au). Ethics committee approval was obtained from the Ethics Committee of Greenslopes Private Hospital (Newdegate Street Greenslopes QL-D 4120 Australia. www.greenslopesprivate.com.au.). Immunohistochemical stains (IHC) were performed at the Queensland Institute of Medical Research (300 Herston Road Herston QLD 4006. Australia. www.qimr.edu.au).

Patients. Relevant clinical details are summarized in Table 1.

Punch biopsies were taken from involved and non-involved skin. Hematoxylin and Eosin stains and immunohistochemistry stains for IDO were fixed in formalin. Quinolinic acid stains were prepared as frozen sections in OCT medium and liquid nitrogen. Immunohistochemical stains were performed at the Queensland Institute of Medical Research histotechnology facility. The protocols were as follows:

Quinolinic acid. Sections were fixed in -20°C acetone for 10 min before being rehydrated in phosphate-buffered saline (PBS), pH 7.4. Endogenous peroxidase activity was blocked by incubating the sections 3.0% H2O2 in PBS for 10 min.

Sections were washed in three changes of PBS for 5 min each and non-specific antibody binding inhibited by incubating the sections in 10% normal goat serum for 30 min.

Abcam rabbit anti-quinolinic acid antibody (ab 37106) was used. Antibody was diluted 1:200 in PBS and applied for 90 min at room temperature, sections washed in three changes of PBS for 2 min each. They were then incubated with Dako Envision Plus anti-rabbit for 30 min at room temperature before being washed in three changes of TBS for 5 min each.

Dako Envision Plus anti-mouse Monoclonal ANTI-FLAG® M2 Peroxidase (HRP) was applied for 30 min before being washed in three changes of TBS for 5 min each.

Color was developed in 3,3′-diaminobenzidine (DAB) with H2O2 as substrate for 5 min and excess chromogen removed by washing in water.

Sections were lightly counterstained in Mayer’s hematoxylin then dehydrated through ascending graded alcohols, cleared in xylene, and mounted.

Positive control was performed on human tonsil non-germinal center tissue looking for cytoplasmic and nuclear labeling in lymphoid cells outside the germinal center. Negative controls were performed using antibody diluent without antibody.

Results
The kynurenine pathway is outlined in Table 2. The initial segment to kynurenine is ubiquitous. The second segment to quinolinic acid is restricted to leucocytes and hepatocytes. The third segment to NAD is restricted to hepatocytes. H and E stains are shown in Figure 1.

Cells of hematopoietic origin. As expected, an infiltrate of inflammatory cells producing quinolinic acid is seen in involved tissue; this is not evident in non-involved tissue (Figs. 2–4). These cells also express IDO (Figs. 5, 6).

Ecocrine units. There are no published reports on kynurenine activity in eccrine units, yet the findings suggest it is an active site. The eccrine units at the control site in patient one showed background activity (Fig. 7). In patient two, the involved site displayed strong expression in the eccrine unit with little or no expression at the control site (Fig. 8). In patient three, there is strong expression in the eccrine unit at the involved site (Fig. 9). This data supports activity of the kynurenine pathway in the eccrine unit. It is of interest that the basement membrane

Table 1. Summary of patient’s clinical features.

| PATIENT | AGE (DECADE) | DURATION (MONTHS) | VARIANT | ANTINUCLEAR ANTIBODY | TREATMENT | SITE |
|---------|--------------|-------------------|---------|----------------------|-----------|------|
| 1       | 5th          | 9                 | Plaque  | Negative             | Phototherapy, methotrexate | Lower back |
| 2       | 7th          | 1                 | Plaque  | Negative             | Nil       | Lower chest |
| 3       | 3rd          | 8                 | Linear  | Negative             | Nil       | Thigh |

Sections were transferred to Dako Antigen retrieval Solution pH 6.0 and heated for 20 min at 100 °C in a Biocare Medical Decloaking Chamber. Slides were removed and allowed to cool for 20 min at room temperature then washed in TBS 3 times for 5 min each.

Non-specific antibody binding was inhibited by the application of 10% goat serum and 1.0% bovine serum albumin (BSA) in TBS for 30 min.

Abcam ab 55305 mouse anti-IDO antibody (0.5 mg/mL) was used. Anti-IDO was diluted 1:150 and applied overnight at room temperature before being washed in three changes of TBS for 5 min each.

Dako Envision Plus anti-mouse Monoclonal ANTI-FLAG® M2 Peroxidase (HRP) was applied for 30 min before being washed in three changes of TBS for 5 min each.

Color was developed in 3,3′-diaminobenzidine (DAB) with H2O2 as substrate for 5 min and excess chromogen removed by washing in water.

Sections were lightly counterstained in Mayer’s hematoxylin then dehydrated through ascending graded alcohols, cleared in xylene, and mounted.

Positive control was performed on human tonsil non-germinal center tissue looking for cytoplasmic and nuclear labeling in lymphoid cells outside the germinal center. Negative controls were performed using antibody diluent without antibody.
The kynurenine pathway in morphea

The kynurenine pathway in morphea

*Initial segment. Ubiquitous in many cell types*
- Tryptophan
- Kynurenine, Kynurenic acid

*Second segment. Limited to leucocytes and hepatocytes*
- 3-Hydroxykynurenine
- 3-Hydroxyanthranilic acid
- Aminocarboxymuconic semialdehyde
- Quinolinic acid

*Third segment. Limited to hepatocytes*
- Nicotinic acid ribonucleotide
- Nicotinamide adenine dinucleotide

Table 2. The kynurenine pathway (Noakes R. Effects of tranilast on the urinary excretion of kynurenic and quinolinic acid under conditions of L-tryptophan loading. *Int J Tryptphan Res.* 2013;6:67–71).

- Initial segment. Ubiquitous in many cell types
- Tryptophan
- Kynurenine, Kynurenic acid

- Second segment. Limited to leucocytes and hepatocytes
- 3-Hydroxykynurenine
- 3-Hydroxyanthranilic acid
- Aminocarboxymuconic semialdehyde
- Quinolinic acid

- Third segment. Limited to hepatocytes
- Nicotinic acid ribonucleotide
- Nicotinamide adenine dinucleotide

zone of the epidermis, eccrine units, and pilosebaceous units are sites of involvement in cutaneous lupus erythematosus. Whether loss of IDO mediated immunological tolerance plays a role in this disorder is speculative but plausible.

**Figure 2.** Patient 1: Quinolinic acid, non-involved (left) and involved (right) x 200.

**Epidermis.** Immunohistochemistry stains support activity of the first two segments of the kynurenine pathway in the basal layer with little evidence of activity in the spinous and granular layers (Fig. 10). It is of interest that one of the described dermatopathological reaction patterns, the lichenoid pattern, is characterized by immunological attack on this zone. Although speculative, it is plausible that kynurenine mediated loss of immunological tolerance may play a role in this reaction pattern.

**Vascular and lymphatics.** IHC stains show evidence of activation of the kynurenine pathway with quinolinic acid synthesis in the endothelium (Fig. 11). IDO activity has previously been reported in endothelium and this data would suggest the second segment of the pathway is also active in endothelium.

**Discussion**

The kynurenine pathway is the metabolic pathway via which L-tryptophan is converted to NAD. L-tryptophan is the least common of the essential amino acids and depletion of it within the microenvironment not only starves cells of an essential amino acid, but can lead to antiproliferative and apoptotic effects on T cells mediated through the GCN2 kinase. The kynurenine metabolites quinolinic acid and 3-hydroxyanthranilic acid suppress T cell proliferation.

In the kynurenine pathway, tryptophan is initially oxidized to formylkynurenine by IDO-1, IDO-2, or tryptophan 2,3-dioxygenase (TDO). The latter is a hepatic enzyme and is induced by tryptophan or corticosteroids. IDO-1 is found extrahepatically and is potently induced by interferon gamma.
The kynurenine metabolites themselves have immunoregulatory roles promoting the apoptosis of Th1, but not Th2 cells. The kynurenine metabolite 3-hydroxyanthranilic acid promotes a cytokine shift in favor of TH2 cells.

Most interest has focused on the role of kynurenine metabolites in neuroinflammation. Kynurenic acid and picolinic acid are neuroprotective whilst quinolinic acid and 3-hydroxyanthranilic acid are neurotoxic.

There are reasons to suggest the kynurenine pathway is active in morphea. Firstly, morphea is associated with eosinophilia and the kynurenine metabolites 3-hydroxyanthranilic acid and quinolinic acid promote a TH2 shift.

Secondly, morphea is often associated with neurological findings. The latter occur most commonly, but not exclusively, in frontoparietal disease. The kynurenine metabolites with the exception of kynurenic acid and picolinic acid are neurotoxic with quinolinic acid mediating its effect through NMDA receptors. Alterations in nerve conduction studies have been reported in morphea.

Finally, generalized scleroderma is associated with Raynaud’s phenomenon or chronic episodic digital ischemia. Although the etiology of this remains controversial, nitric oxide has been reported to play a role and 3-hydroxyanthranilic acid is known to inhibit the expression and activity of inducible nitric oxide synthase.

Although the causes of most cases are unknown, morphea has been reported to follow vaccination, radiotherapy, and infections, all known inducers of interferon gamma production, the main inducer of IDO-1. Histologically early lesions of morphea display a superficial and deep inflammatory lymphocytic infiltrate and it is possible that the infiltrating lymphocytes are responsible for the production of interferon gamma.

We have previously published on the results of quinolinic acid injections in a human volunteer. Both a peripheral eosinophilia and an interstitial infiltrate of eosinophils were reported. TGF-beta production by dermal dendrocytes and endothelial cells was noted. Elevated levels of the fibrotic cytokine TGF-beta is found in morphea. TGF-beta 1, 2 and 3 are secreted by most cell types, generally in a latent form, requiring activation before they can exert biological activity. This activation of latent TGF-beta, which may involve plasmin, thrombospondin, and possibly acidic microenvironments, appears to be a crucial regulatory step in controlling their effects. Regrettably, there exists little published data on associations between kynurenine metabolites and possible activation of the TGF-betas, although it is likely both are entwined due to their immunosuppressive properties. There are reported alteration in the kynurenine pathway in the hyper-fibrinolytic states seen in chronic renal failure patients on dialysis, which could potentially suggest that they play a
role in plasminogen conversion to plasmin and activation of latent TGFs. This is, however, speculative.

Our results indicate both IDO and quinolinic acid are expressed in the basal layer of the epidermis, eccrine units, and vascular endothelium in addition to infiltrating inflammatory cells. The concentration of metabolites in the microenvironment is likely to be critical in disease states as the kynurenine pathway is a physiological metabolic pathway and pathological consequences should not be seen at physiological concentrations. The importance of concentration has already been reported in relation to the neurotoxic effects of quinolinic acid. It is of interest that the adnexal structures, which are lost in morphea, correspond to the site of maximal activity of the kynurenine pathway supporting an etiological role.

Thus we provide data to support evidence of activation of the kynurenine pathway in morphea.

The question as to whether the kynurenine pathway is responsible for the increased synthesis and activation of TGFs beta in morphea is more difficult to answer. It is suggested, however, by the overlap between eosinophilia myalgia syndrome and eosinophilic fasciitis, which is now included in the spectrum of localized scleroderma.

The issue would be best answered by demonstrating that manipulation of this pathway produced clinical improvement. There is already some data, albeit mixed, available on this. Tranilast, a 3 hydroxyanthranilic acid analogue, has been reported to be of benefit in anecdotal reports and has marketing approval for treatment of keloid scars in Japan. None the less, definitive answers require further investigation.

The principal limitations of this study are the small number of patients and the dynamic nature of the system under investigation with IHC studies providing a snapshot only. This may not be representative of the behavior of the system over a longer time frame.

Author Contributions
Conceived and designed the experiments: RN, NM. Analyzed the data: RN, NM. Wrote the first draft of the manuscript: RN, NM. Contributed to the writing of the manuscript: RN, NM. Agree with manuscript results and conclusions: RN, NM. Jointly developed the structure and arguments for the paper: RN, NM. Made critical revisions and approved final version: RN, NM. All authors reviewed and approved of the final manuscript.

DISCLOSURES AND ETHICS
As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research
participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. This article was subject to blind, independent, expert peer review. The reviewers reported no competing interests.

REFERENCES

1. Freundlich B, Werth VP, Rook AH, et al. L-tryptophan ingestion associated with eosinophilic fascitis but not progressive systemic sclerosis. Ann Intern Med. 1990;112(10):758–62.
2. Grigoris I, de Launey W, Jevtic AP. Eosinophilic fascitis associated with L-tryptophan ingestion. Med J Aust. 1992 Sep;157(5):329–30.
3. Martin BW, Dufy J, Engel AG, et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med. 1990;113(2):124–34.
4. Mayeno AN, Lin F, Foote CS, et al. Characterization of “peak E,” a novel amino acid associated with eosinophilia-myalgia syndrome. Science. 1990;250(4988):1707–8.
5. Blauvelt A, Falanga V. Idiopathic and L-tryptophan-associated eosinophilic fascitis before and after L-tryptophan contamination. Arch Dermatol. 1991;127(8):1159–66.
6. Silver RM, McKinley K, Smith EA, et al. Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome. Arthritis Rheum. 1992;35(9):1097–105.
6. Silver RM, Sutherland SE, Carreira P, Heyes MP. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome. J Rheumatol. 1992;19(1):69–73.
8. Noakes R, Spelman L, Williamson R. Is the L-tryptophan metabolite quinolinic acid responsible for eosinophilic fascitis? Clin Exp Med. 2006;6(2):60–4.
9. Nahm WK, Philpot BD, Adams MM, et al. Significance of N-methyl-D-aspartate (NMDA) receptor-mediated signaling in human keratinocytes. J Cell Physiol. 2004;200(2):309–17.
10. Asp L, Johansson AS, Mann A, et al. Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts. J Inflamm (Lond). 2011;8:25.
11. Guillemín GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol. 2004;75(3):388–97.
12. Fujigaki H, Saito K, Lin F, et al. Nitration and inactivation of IDO by peroxynitrite. J Immunol. 2006;176(3):372–9.
13. Moffett JR, Nambudiri MA. Tryptophan and the immune response. Immuno Cell Biol. 2003;31(4):247–65.
14. Yasui H, Takai K, Yoshida R, Hayashi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci U S A. 1986;83(17):6622–6.
15. Dai W, Gupta SL. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. J Biol Chem. 1990;265(32):19871–7.
16. Marttila S, Jylhävä J, Eklund C, Hervonen A, Jylhä M, Hurme M. Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells. Immun Ageing. 2011;8:9.
17. Meyer KC, Klatte JE, Dinh HV, et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol. 2010;163(5):1077–85.
18. Wang Y, Liu H, McKenzie G, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010;16(3):279–85.
19. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol. 1991;294:425–35.
20. Pfeiffer Ron ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A. 1992;89(22):10468–72.
21. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology. 2002;107(4):452–60.
22. Munn DH, Sharma MD, Buban B, et al. GCN2 kinase in T cells mediates proliferative arrest and energy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22(5):633–42.
23. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by kynurenines. Adv Exp Med Biol. 2003;527:183–90.
24. Meitz R, Dihadzawa MB, Kamansu U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67(5):7082–7.
25. Salter M, Pogson CI. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J. 1985;229(2):499–504.
26. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9(10):1069–77.
27. Platten M, Ho PF, Youssef S, et al. Treatment of autoimmune immune inflammation with a synthetic tryptophan metabolite. Science. 2005;310(5749):850–5.
28. Moroni F, Russi P, Lombardi G, Beni M, Carta V. Presence of kynurenic acid in the mamalian brain. J Neurochem. 1988;51(1):177–80.
29. Jhamandas K, Boegrm J, Beninger RJ, Balik M. Quinolinic-induced cortical cholinergic damage: modulation by tryptophan metabolites. Brain Res. 2002;936(1–2):15–21.
30. Kim JP, Choi DW. Quinolinate neurotoxicity in cortical cell culture. Neuroscience. 1987;23(2):423–32.
31. Christen-Zaech S, Hakim M, Afsar S, Paller A. Pediatric morphea (localized scleroderma): Review of 136 patients. J Am Acad Dermatol. 2008;59:385–96.
32. Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 1981;72:411–2.
33. Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005 Sep;52(9):2873–81.
34. Sekkai D, Guittet O, Lemaire G, Tenu JP, Lopoivre M. Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. Arch Biochem Biophys. 1997;340:117–23.
35. Killoran C, Falanga V. Morphoea. Dermatology in General Medicine. 7th Ed. Pp 543.
36. Lawrence DA. Transforming growth factor-beta: a general review. Eur Cytokine Netw. 1996;7(3):363–74.
37. Belladonna ML, Orahona, Grohmann U and Puccetti P. TGF-β and kynurenines as the key to infectious tolerance. Trends in Molecular Medicine. January 21, 2009; 15(2):41–9.
38. Pawlak K, Mysliwiec M, Pawlak D. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients Thromb Res. 2010 Feb;125(2):e40–5. Epub September 3, 2009.
39. Guillemín GJ, et al. Indoleamine 2,3-dioxygenase and quinolinic acid immune-necrotic activity in Alzheimer’s disease hippocampus. Neuropath Appl Neurobiol. 2005;31(4):395–404.
40. Taniguchi S, Yorifuji T, Hamada T. Treatment of linear localized scleroderma with the anti- allergic drug, tranilast. Clin Exp Dermatol. 1994 Sep;19(5):391–3.